A clinical trial to study the effects of moxifloxacin with regular anti-tuberculosis drugs in Tuberculosis patients
Not Applicable
- Conditions
- Health Condition 1: null- Newly diagnosed Tuberculosis Patients and relapse TB cases with no resistance
- Registration Number
- CTRI/2016/03/006713
- Lead Sponsor
- Vijey Aanandhi M
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 131
Inclusion Criteria
1.Patients who are newly diagnosed with pulmonary tuberculosis
2.Patients with relapse of tuberculosis
Exclusion Criteria
1.Patients with known resistance for at-least one of the four first line drugs.
2.Patients with Extra-pulmonary tuberculosis
3.Pregnant and nursing women
4.Known allergy to any fluoroquinolone antibiotic or history of tendinopathy associated with fluoroquinolones.
5.Patients already receiving anti-retroviral therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Moxifloxacin arm is expected to show rapid sputum negativity.Timepoint: At the end of 2 months(intensive phase) and at the end of 6 months ( continuation phase)
- Secondary Outcome Measures
Name Time Method Measurement of Adverse drug eventsTimepoint: Every week of follow up